Table 1 Patient characteristics prior to CPDG2 administration
From: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure
Patient characteristics | Study entry | Prior CPDG 2 treatment | Serum creatinine ( μ mol l−1) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Underlying disease | Number of patients ( n) | Sex (female/male) | Age (years median range) | MTX dose (g m−2) | MTX infusion time (h) | Intrathecal MTX therapy ( n) | MTX serum level ( μ M ) (median (range)) | Time from start of MTX infusion (h) (median (range)) | MTX serum level ( μ M ) (median (range)) | Time from start of MTX infusion (h) (median (range)) | Prior to MTX infusion (median (range)) | At study entry (median (range)) | Prior to CPDG 2 treatment (median (range)) |
All patients | 65 | 24/41 | 15.4 (0.9–71.8) | 1–12 | 4–36 | 24 | 18 (0.52–1082) | 47 (19–142) | 11.93 (0.52–901) | 52 (25–178) | 61.1 (17.7–156.6) | 185.6 (44.3–516.8) | 177.9 (53.1–652.3) |
ALL | 26 | 8/18 | 14.1 (2.6–71.8) | 1–8 | 6 (n=1), 24 (n=23), 36 (n=2) | 18 | 18 (0.52–287) | 48 (20–108) | 10.66 (0.52–228) | 52 (25–120) | 45.1 (17.7–115.1) | 99.12 (35.4–220.4) | 136.3 (53.1–516.8) |
NHL/Hodgkin's lymphoma | 21/2 | 9/14 | 53.3 (4.3–68.9) | 3–8 | 4–8 (n=10), 24 (n=13) | 5 | 13.94 (1–420) | 45 (26–142) | 7.46 (0.8–260) | 55 (34–178) | 70.8 (35.4–144.3) | 208.9 (44.3–513.3) | 218.6 (44.3–513.3) |
Osteosarcoma | 12 | 4/8 | 15.3 (9.4–39.4) | 12 | 4 (n=12) | 248 (2.43–1082) | 38.5 (19–70.5) | 177 (2.43–901) | 46 (25–78) | 73.5 (35.4–156.6) | 172.6 (88.5–516.8) | 197.4 (88.5–652.3) | |
Brain tumour/pleural mesothelioma | 3/1 | 3/1 | 12.2 (0.9–20.3) | 3–5 | 4 (n=1), 24 (n=3) | 1 | 3.6 (2.39–17.4) | 58 (44.5–66) | 2.45 (1.93–17.4) | 64.5 (45–82) | 63.7 (44.3–97.4) | 105.3 (62–380.6) | 127.4 (62–407.1) |
